首页 | 本学科首页   官方微博 | 高级检索  
检索        

索拉菲尼联合放疗治疗原发性肝癌的研究进展
引用本文:李广欣,张建忠,黎功.索拉菲尼联合放疗治疗原发性肝癌的研究进展[J].国际肿瘤学杂志,2012,39(8):615-618.
作者姓名:李广欣  张建忠  黎功
作者单位:100141,武警北京总队第三医院肿瘤科
摘    要: 适形放疗是原发性肝癌局部治疗的重要手段之一,但放疗后肝内、肝外转移率较高。索拉菲尼是目前肝癌治疗中惟一被证实有效的药物,可提高晚期肝癌患者的总生存期。索拉菲尼联合放疗,可提高肿瘤细胞辐射敏感性、抑制血管生成、缓解肿瘤乏氧状态、使细胞周期同步化。索拉菲尼联合放疗,已进行了大量生物学研究,Ⅰ、Ⅱ期临床试验也正在开展。

关 键 词:放射疗法  肝肿瘤  索拉菲尼  

Sorafenib combined with radiotherapy for primary hepatic carcinoma
LI Guang-xin , ZHANG Jian-zhong , LI Gong.Sorafenib combined with radiotherapy for primary hepatic carcinoma[J].Journal of International Oncology,2012,39(8):615-618.
Authors:LI Guang-xin  ZHANG Jian-zhong  LI Gong
Institution:Oncology Department, Third Hospital of Beijing Armed Police Corps, Beijing 100141, China
Abstract:Conformal radiotherapy is an important therapeutic strategy for primary hepatic carcinoma, which has high local control rate. However, the frequency of intra- and extra-epatic recurrences is very high. Sorafenib is the only drug that has been demonstrated effectiveness to increase overall survival in advanced or metastatic hepatocellular carcinoma. The combination about radiotherapy and sorafenib can increase the radiosensitiveness,and inhibit the angiogenesis,and relieve the hypoxia, as well as synchronize the cell cycle. A lot of biological studies of sorafenib combined with radiotherapy have been carried out, and the phase Ⅰ-Ⅱclinical trials are is in progress.
Keywords:Radiotherapy  Liver neoplasms  Sorafenib
本文献已被 万方数据 等数据库收录!
点击此处可从《国际肿瘤学杂志》浏览原始摘要信息
点击此处可从《国际肿瘤学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号